Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
Black Rock Inc. New York, NY14.7MShares$714 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$572 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$471 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$378 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$314 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC4.83MShares$235 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.16MShares$154 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA2.85MShares$139 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$132 Million2.29% of portfolio
-
Polar Capital Holdings PLC London, X02.34MShares$114 Million0.76% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
742
-2.93%
|
$35,616
$48.61 P/Share
|
|
Dec 16
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+2.85%
|
$5,194
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,872
+10.72%
|
$83,104
$7.37 P/Share
|
|
Dec 11
2024
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
1,780
-4.42%
|
$89,000
$50.42 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.99%
|
$365,000
$50.64 P/Share
|
|
Dec 10
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.12%
|
$37,100
$7.96 P/Share
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,607
+9.64%
|
-
|
|
Dec 03
2024
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,536
-3.94%
|
$78,336
$51.51 P/Share
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,530
+3.99%
|
-
|
|
Dec 03
2024
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-1.5%
|
$13,923
$51.51 P/Share
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+3.3%
|
-
|
|
Dec 03
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,028
-1.75%
|
$103,428
$51.51 P/Share
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,353
+4.47%
|
-
|
|
Dec 03
2024
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,351
-2.01%
|
$68,901
$51.51 P/Share
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,059
+2.72%
|
-
|
|
Dec 03
2024
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,843
-1.43%
|
$297,993
$51.51 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.76 P/Share
|
|
Dec 02
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.1%
|
$365,000
$50.15 P/Share
|
|
Nov 26
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.26%
|
$37,100
$7.96 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 267K shares |
|---|---|
| Exercise of conversion of derivative security | 378K shares |
| Open market or private sale | 502K shares |
|---|---|
| Payment of exercise price or tax liability | 80.8K shares |
| Bona fide gift | 2.11K shares |